Differential frequency of persister cells in clinically derived isolates of <i>Pseudomonas aeruginosa</i> after exposure to cefiderocol and ceftolozane/tazobactam
Cefiderocol resulted in less bacterial persistence relative to ceftolozane/tazobactam against nine clinical P. aeruginosa isolates. Cefiderocol's siderophore mechanism may be advantageous over ceftolozane/tazobactam through enhanced anti-persister effects. Clinical correlation of these findings is warranted as persisters can lead to antibiotic resistance and treatment failure.
Authors
- Samantha Nicolau
- Christian M Gill (ORCID: https://orcid.org/0000-0003-3606-0761)
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Pranita D. Tamma (ORCID: https://orcid.org/0000-0002-4143-6324)
- Patricia J. Simner (ORCID: https://orcid.org/0000-0001-6134-151X)
Institutions
- Hartford Hospital (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sanofi (United States) (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1093/jac/dkae346
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.17
Funders
- Shionogi